Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 29.
doi: 10.1007/s10557-024-07587-9. Online ahead of print.

Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review

Chen Chen  1   2   3 , Fang-Fei Wei  4   5   6 , Yugang Dong  7   8   9 , Chen Liu  10   11   12
Affiliations
Review

Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review

Chen Chen et al. Cardiovasc Drugs Ther. .

Abstract

Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality, despite many improvements in its prevention and management. Lipid management is an important aspect of secondary prevention after ACS. Previous studies indicate that the early use of intensive statin therapy in patients with ACS may alleviate the risk of recurrent cardiovascular events and mortality. However, many patients do not reach the target low-density lipoprotein cholesterol (LDL-C) level of < 55 mg/dL with statin monotherapy, and muscle-related adverse effects caused by statins hinder adherence to treatment. Novel non-statin agents are recommended for patients who cannot achieve the target LDL-C levels with high-intensity statin therapy and those with statin intolerance. The combination of statins and non-statins may synergistically affect intensively lowering LDL-C through different mechanisms, which could lead to better cardiovascular outcomes than statin monotherapy. However, it remains uncertain whether the early use of combination lipid-lowering therapy is more beneficial. The present review summarizes the benefits of intensive statin monotherapy and their early combination with non-statin medications including ezetimibe, PCSK9 inhibitors, inclisiran, and bempedoic acid (BDA) in the management of ACS.

Keywords: Acute Coronary Syndrome; Early Management; Lipid-lowering Therapy; Non-statins; Statins.

PubMed Disclaimer

References

    1. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917–38. https://doi.org/10.1016/S0025-6196(11)60509-0 . - DOI - PubMed - PMC
    1. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-Month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation myocardial infarction) 1995 to 2015. Circulation. 2017;136(20):1908–19. https://doi.org/10.1161/CIRCULATIONAHA.117.030798 . - DOI - PubMed
    1. Claessen BE, Guedeney P, Gibson CM, et al. Lipid management in patients presenting with Acute Coronary syndromes: a review. J Am Heart Assoc. 2020;9(24):e018897. https://doi.org/10.1161/JAHA.120.018897 . - DOI - PubMed - PMC
    1. Association CMD. Expert consensus on clinical pathway of blood lipid management in patients with acute coronary syndrome. J Cardiol Plus. 2020;5(3):130. - DOI
    1. Huo Y, Lee SW, Sawhney JPS, et al. Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: findings from the EPICOR Asia study. Int J Cardiol. 2020;315:1–8. https://doi.org/10.1016/j.ijcard.2020.05.022 . - DOI - PubMed

LinkOut - more resources